This article is more than 5 years old. Information may no longer be current.
Oraya Therapy maintains vision, reduces injections in wet AMD treatment at 1 year
Click Here to Manage Email Alerts
Oraya Therapy maintained vision and reduced the number of anti-VEGF injections in the treatment of wet age-related macular degeneration, according to an Oraya Therapeutics press release.
The 1-year results, presented at the Euretina meeting, showed chronic patients had a 40% to 74% reduction in the number of injections with a significant decrease in macular edema. Newly diagnosed patients experienced significantly better vision compared with those in a historical control group.
In the single treatment of Oraya Therapy, the IRay stereotactic radiotherapy system delivers highly targeted, low-energy X-rays to the diseased area of the eye to act in conjunction with existing anti-VEGF treatments to counter proliferation of the neovascular lesion.
More than 500 patients have been treated with Oraya Therapy across Switzerland, Germany and
the United Kingdom, and the company is looking to expand the number of clinics in the coming months, the release said.
The IRay radiotherapy system is a CE marked medical device but is only an investigational device in the U.S., the release said.